Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144637 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
A Phase 3 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,005
- Enrollment target
NCT01144637 is a Phase 3 study that has completed, run by Bavarian Nordic. The registered enrollment target is 4,005 participants.
The verdict
NCT01144637, a Phase 3 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,005 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.
Interventions
- OTHER Placebo
- BIOLOGICAL IMVAMUNE®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,005 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144637
The ClinicalTrials.gov registry entry for NCT01144637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,005 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01144637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144637 about?
NCT01144637 is a clinical study titled "A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects". A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.
What is the current status of trial NCT01144637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,005 participants. The study started on 2013-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01144637?
The interventions under investigation include: Placebo (OTHER), IMVAMUNE® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01144637?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.